0000899243-20-009854.txt : 20200401
0000899243-20-009854.hdr.sgml : 20200401
20200401171619
ACCESSION NUMBER: 0000899243-20-009854
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200330
FILED AS OF DATE: 20200401
DATE AS OF CHANGE: 20200401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Goeltz II Robert C.
CENTRAL INDEX KEY: 0001653881
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38470
FILM NUMBER: 20766306
MAIL ADDRESS:
STREET 1: 343 OYSTER POINT BLVD
STREET 2: SUITE 100
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unity Biotechnology, Inc.
CENTRAL INDEX KEY: 0001463361
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264726035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: (415) 328-5504
MAIL ADDRESS:
STREET 1: 3280 BAYSHORE BOULEVARD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: Cenexys, Inc.
DATE OF NAME CHANGE: 20130703
FORMER COMPANY:
FORMER CONFORMED NAME: Forge Inc
DATE OF NAME CHANGE: 20090504
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-03-30
0
0001463361
Unity Biotechnology, Inc.
UBX
0001653881
Goeltz II Robert C.
C/O UNITY BIOTECHNOLOGY, INC.
285 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Financial Officer
Common Stock, $0.0001 par value
2020-03-30
4
A
0
29106
0.00
A
163510
D
Stock Option (Right to Buy)
5.95
2020-03-30
4
A
0
118188
0.00
A
2030-03-29
Common Stock
118188
118188
D
Represents Restricted Stock Units ("RSUs") which vest in equal annual installments over a three year period measured from March 30, 2020. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
Includes RSUs which vest over time measured from the grant date.
Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on March 30, 2020 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
/s/ Tamara L. Tompkins, Attorney-in-Fact for Robert C. Goeltz II
2020-04-01